Testicular leiomyosarcoma – Diagnostics – Overview of Information and Clinical Research

Testicular leiomyosarcoma is an extremely rare cancer that develops in the smooth muscle tissue of the testicle or surrounding structures. Because it occurs so infrequently, diagnosing this condition requires careful examination and specialized testing. Understanding when to seek medical attention and what diagnostic tests may be needed can help ensure prompt and accurate diagnosis.

Introduction: Who Should Undergo Diagnostics

Anyone who notices a lump, swelling, or change in their testicle should seek medical evaluation promptly. Testicular leiomyosarcoma typically presents as a painless, gradually enlarging mass in the scrotum, though some patients may experience mild discomfort or a feeling of heaviness. The condition can affect men of various ages, though it is more commonly diagnosed in middle-aged and older individuals, with an average age of presentation around 50 years.^[1]

While most testicular lumps turn out to be benign conditions or more common types of testicular cancer, any persistent scrotal mass warrants immediate medical attention. Young men without typical risk factors can also develop this condition, making it important not to delay seeking care based on age alone.^[1] Some patients may initially mistake their symptoms for infections like epididymo-orchitis, leading them to try antibiotic treatment without improvement.^[4]

Men with certain risk factors should be particularly vigilant about changes in their testicles. These risk factors include previous radiation therapy to the testicular area, long-term use of high-dose anabolic steroids, chronic testicular inflammation, or a history of testicular germ cell tumors.^[1] However, many cases occur in individuals without any known predisposing factors, so any concerning symptoms should prompt a visit to a healthcare provider.^[3]

⚠️ Important

Do not wait to see if a testicular lump goes away on its own. Early diagnosis is crucial for the best possible outcome. Most testicular masses require professional evaluation, and delaying care can potentially complicate treatment. If you notice any lump, swelling, or persistent change in your testicle, schedule an appointment with your doctor right away.

Diagnostic Methods: Identifying Testicular Leiomyosarcoma

Physical Examination

The diagnostic process typically begins with a thorough physical examination. A doctor will carefully feel the testicle, scrotum, and surrounding areas to assess the size, consistency, and location of any mass. During this examination, they will check whether the mass is hard or soft, whether it is attached to the testicle itself or to surrounding structures like the spermatic cord, and whether there is any tenderness or signs of infection.^[2] The physician will also examine the abdomen and lymph nodes to check for any signs of disease spread.

In cases of testicular leiomyosarcoma, the examination typically reveals a hard, non-tender mass. The spermatic cord may feel normal, which helps distinguish this condition from masses that originate in the cord itself.^[3] Some patients present with larger masses that have grown over months or even years before seeking medical attention.^[5]

Ultrasound Imaging

After the physical examination, scrotal ultrasound is usually the first imaging test ordered. This non-invasive test uses sound waves to create detailed pictures of the inside of the scrotum and testicles. An ultrasound can help determine whether a mass is solid or fluid-filled, where exactly it is located, and how large it is. In testicular leiomyosarcoma, ultrasound typically shows a hypoechoic mass, meaning it appears darker than normal testicular tissue on the scan.^[1]

The ultrasound may reveal that the mass has both solid and cystic (fluid-filled) components. It also helps assess whether the opposite testicle is normal and whether the epididymis or spermatic cord shows any abnormalities.^[3] While ultrasound is excellent for visualizing testicular masses, it cannot definitively determine whether a mass is cancerous or what specific type of cancer it might be. However, it provides crucial information that guides the next steps in diagnosis and treatment.

Blood Tests for Tumor Markers

Blood tests play an important role in evaluating testicular masses because they can measure levels of certain substances called tumor markers. For testicular cancers, doctors commonly check three markers: alpha-fetoprotein (AFP), beta human chorionic gonadotropin (β-HCG), and lactate dehydrogenase (LDH). These markers are proteins that can be elevated in many types of testicular germ cell tumors.^[1]

In testicular leiomyosarcoma, these tumor markers are typically within normal limits. This is a key distinguishing feature that helps differentiate leiomyosarcoma from more common testicular cancers like seminomas or non-seminomatous germ cell tumors, which often cause elevated marker levels.^[2] Normal tumor marker levels, combined with imaging findings, can suggest that the mass might be a sarcoma or other non-germ cell tumor, but they do not provide a definitive diagnosis.^[3]

CT Scanning for Disease Staging

Once a testicular mass is identified and surgery is being planned, doctors typically order computed tomography (CT) scans of the abdomen, pelvis, and chest. These scans help determine whether the cancer has spread beyond the testicle to lymph nodes or other organs. CT scans use X-rays taken from multiple angles to create detailed cross-sectional images of the body.^[1]

In most cases of testicular leiomyosarcoma diagnosed at early stages, CT scans show no evidence of metastatic disease, meaning the cancer has not spread to other parts of the body. The scans specifically look for enlarged lymph nodes in the retroperitoneum (the area behind the abdominal organs), as well as any masses in the lungs, liver, or other organs.^[3] This information is crucial for determining the stage of the disease and planning appropriate treatment.

Histopathologic Examination and Immunohistochemistry

The definitive diagnosis of testicular leiomyosarcoma can only be made through examination of tissue under a microscope, a process called histopathology. This examination occurs after surgical removal of the affected testicle through a procedure called radical inguinal orchiectomy. The entire testicle and attached spermatic cord are removed and sent to a pathologist for analysis.^[1]

Under the microscope, leiomyosarcoma shows characteristic features including spindle-shaped cells arranged in interlacing bundles or fascicles. These cells have elongated nuclei and abundant eosinophilic (pink-staining) cytoplasm that reflects their smooth muscle origin. The pathologist looks for signs of malignancy such as nuclear pleomorphism (variation in nucleus size and shape), increased numbers of mitotic figures (dividing cells), and areas of tissue death called necrosis.^[4]

Because spindle cell tumors in the testicle can have various origins, pathologists use a technique called immunohistochemistry to confirm the diagnosis. This involves applying special antibodies to the tissue samples to see which proteins the tumor cells produce. Leiomyosarcoma cells typically test positive for markers of smooth muscle, including desmin, smooth muscle actin (SMA), and h-caldesmon. They are usually negative for markers like S-100 (found in nerve tumors) and CD117 (found in other types of tumors).^[3]

The pathologist also assigns a grade to the tumor based on how abnormal the cells look and how many are dividing. High-grade tumors have more abnormal-appearing cells and more mitotic activity, suggesting more aggressive behavior, while low-grade tumors appear closer to normal tissue and tend to grow more slowly.^[1]

Diagnostics for Clinical Trial Qualification

When patients with testicular leiomyosarcoma are being considered for enrollment in clinical trials, additional or repeated diagnostic tests may be required beyond standard clinical care. Clinical trials have specific entry criteria that must be documented through testing before a patient can participate.

Comprehensive Imaging and Staging

Clinical trials typically require comprehensive baseline imaging to precisely document the extent of disease before any experimental treatment begins. This usually includes CT scans of the chest, abdomen, and pelvis performed within a specified timeframe before enrollment, often within four weeks of starting the trial. Some trials may also require additional imaging modalities such as magnetic resonance imaging (MRI) or positron emission tomography (PET) scans to better characterize the tumor or detect spread of disease that might not be visible on CT scans alone.

These imaging studies establish a baseline against which the effectiveness of the trial treatment can be measured. Detailed measurements of any tumors present are recorded, and follow-up scans at specified intervals during the trial will show whether the treatment is shrinking the tumors, keeping them stable, or failing to control their growth. Trials may have specific requirements about tumor size or location for eligibility.

Tissue Sample Requirements

Many modern clinical trials, particularly those testing targeted therapies or immunotherapies, require tissue samples from the patient’s tumor for molecular or genetic analysis. For testicular leiomyosarcoma, this typically means providing a portion of the tissue that was removed during the original orchiectomy. The tissue is analyzed to look for specific genetic mutations, protein expressions, or other molecular features that might predict response to the treatment being studied.

Some trials may require a fresh biopsy, meaning tissue obtained recently rather than stored samples from previous surgeries. This is more common when the disease has recurred or spread, as the characteristics of the cancer cells may have changed over time or with treatment. The pathology report confirming the diagnosis of leiomyosarcoma with immunohistochemistry is always required for trial enrollment.

Organ Function Testing

Clinical trials have strict eligibility requirements regarding organ function to ensure patient safety during experimental treatments. Before enrollment, patients typically undergo blood tests to assess kidney function, liver function, and bone marrow function. These include tests measuring creatinine (kidney function), liver enzymes such as ALT and AST, bilirubin levels, and complete blood counts to check red blood cells, white blood cells, and platelets.

Many trials also require baseline testing of heart function, particularly if the treatment being studied could potentially affect the heart. This might include an electrocardiogram (ECG or EKG) to check the heart’s electrical activity, or an echocardiogram (ultrasound of the heart) to assess how well the heart is pumping. These baseline measurements help identify any pre-existing problems that might make certain treatments unsafe, and they provide comparison points for monitoring during the trial.

Performance Status Assessment

Clinical trials assess a patient’s overall health and ability to perform daily activities using standardized scales like the Eastern Cooperative Oncology Group (ECOG) performance status or the Karnofsky performance scale. These assessments help ensure that patients enrolled in trials are healthy enough to tolerate the treatments being studied. The evaluation includes questions about the patient’s ability to care for themselves, walk, work, and carry out daily activities without assistance.

Most early-phase trials require patients to have good performance status, meaning they are fully active or only slightly limited in their activities. Later-phase trials may have more flexible requirements, but some minimum level of function is typically required to ensure patient safety and the ability to complete the trial protocol.

Prognosis and Survival Rate

Prognosis

The prognosis for testicular leiomyosarcoma varies significantly based on several factors, most importantly the tumor grade and whether the cancer has spread beyond the testicle. Tumors are typically classified as either cutaneous or subcutaneous based on their origin. Cutaneous leiomyosarcoma, which originates from the arrector pili muscle of hair follicles or the dartos muscle of scrotal skin, generally has a better outlook. Subcutaneous leiomyosarcoma, which arises from smooth muscle of deeper structures or blood vessels, tends to have a higher risk of spreading and recurring.^[9]

Tumor grade is one of the most significant factors affecting prognosis. Low-grade tumors have cells that look relatively normal under the microscope and tend to grow slowly. These tumors rarely spread to other parts of the body and generally respond well to surgical removal, with excellent long-term outcomes.^[12] High-grade tumors, on the other hand, have cells that appear very abnormal, divide rapidly, and behave more aggressively. These tumors have a higher risk of both local recurrence and distant spread to lymph nodes, lungs, or liver in about one-third of cases.^[4]

The completeness of surgical removal also significantly impacts prognosis. Patients who have surgery that achieves clear margins, meaning no cancer cells are visible at the edges of the removed tissue, have much better outcomes than those with microscopic cancer remaining at the surgical margin.^[9] When treated early with complete surgical removal, many patients with testicular leiomyosarcoma can be cured, particularly if the tumor is low-grade and has not spread beyond the testicle.^[11]

Most cases of primary testicular leiomyosarcoma are diagnosed at an early stage, before the cancer has spread. These patients typically have a favorable prognosis with appropriate treatment. Primary intratesticular sarcomas generally behave indolently, meaning they grow slowly, and have rare potential for distant spread.^[1] However, individual outcomes can vary, and regular monitoring after treatment remains essential because recurrence can occur months or even years after initial treatment.^[4]

Survival rate

Long-term survival data for testicular leiomyosarcoma specifically is limited because the condition is so rare. However, available evidence suggests that outcomes can be quite good when the disease is caught early and treated appropriately. For paratesticular leiomyosarcomas in general, which include tumors of the testicle, spermatic cord, and scrotal tissues, the long-term survival rate is approximately 50%.^[12]

Survival rates vary dramatically based on tumor characteristics and stage at diagnosis. Low-grade testicular leiomyosarcomas rarely recur or spread to distant sites and have an excellent prognosis, with most patients achieving long-term disease-free survival after surgery alone.^[12] The outlook for these patients is similar to that for benign conditions, with near-normal life expectancy.

For high-grade tumors, the prognosis is more guarded. About one-third of patients with high-grade paratesticular leiomyosarcomas experience either local recurrence or distant spread.^[12] However, even among these patients, many can be successfully treated with additional surgery, radiation therapy, or systemic treatments. The specific survival rate depends on factors including how quickly the disease is diagnosed, whether complete surgical removal is possible, and how well the tumor responds to any additional treatments needed.

It’s important to understand that statistics represent averages across many patients and cannot predict what will happen in any individual case. Factors such as overall health, age, access to specialized care, and the specific characteristics of the tumor all influence outcomes. Early detection and treatment at centers with experience managing rare sarcomas can significantly improve the chances of a favorable outcome.

#1 Clinical Trials Search in Europe